Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 23840830)


HIV-1 clade B pol evolution following primary infection.

Hightower GK, May SJ, Pérez-Santiago J, Pacold ME, Wagner GA, Little SJ, Richman DD, Mehta SR, Smith DM, Pond SL.

PLoS One. 2013 Jun 28;8(6):e68188. doi: 10.1371/journal.pone.0068188. Print 2013.


Intra-host evolutionary rates in HIV-1C env and gag during primary infection.

Novitsky V, Wang R, Rossenkhan R, Moyo S, Essex M.

Infect Genet Evol. 2013 Oct;19:361-8. doi: 10.1016/j.meegid.2013.02.023. Epub 2013 Mar 20.


HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy.

Lihana RW, Khamadi SA, Lubano K, Lwembe R, Kiptoo MK, Lagat N, Kinyua JG, Okoth FA, Songok EM, Makokha EP, Ichimura H.

AIDS Res Hum Retroviruses. 2009 Dec;25(12):1211-7. doi: 10.1089/aid.2009.0007.


Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.


Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1.

Knapp DJ, Brumme ZL, Huang SY, Wynhoven B, Dong WW, Mo T, Harrigan PR, Brumme CJ.

Clin Infect Dis. 2012 Jun;54(11):1652-9. doi: 10.1093/cid/cis253. Epub 2012 Mar 28.


Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa.

Brumme Z, Wang B, Nair K, Brumme C, de Pierres C, Reddy S, Julg B, Moodley E, Thobakgale C, Lu Z, van der Stok M, Bishop K, Mncube Z, Chonco F, Yuki Y, Frahm N, Brander C, Carrington M, Freedberg K, Kiepiela P, Goulder P, Walker B, Ndung'u T, Losina E.

Clin Infect Dis. 2009 Sep 15;49(6):956-64. doi: 10.1086/605503.


Impact of HLA selection pressure on HIV fitness at a population level in Mexico and Barbados.

Juarez-Molina CI, Payne R, Soto-Nava M, Avila-Rios S, Valenzuela-Ponce H, Adland E, Leitman E, Brener J, Muenchhoff M, Branch S, Landis C, Reyes-Teran G, Goulder P.

J Virol. 2014 Sep;88(18):10392-8. doi: 10.1128/JVI.01162-14. Epub 2014 Jul 9.


Characterization of GBV-C infection in HIV-1 infected patients.

Canducci F, Uberti Foppa C, Boeri E, Racca S, Gallotta G, Grasso MA, Calori G, Lazzarin A, Clementi M.

J Biol Regul Homeost Agents. 2003 Apr-Jun;17(2):191-4.


Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women.

Kelley CF, Sullivan ST, Lennox JL, Evans-Strickfaden T, Hart CE.

AIDS. 2010 Jun 1;24(9):1361-6. doi: 10.1097/QAD.0b013e3283394f3f.


Characterizing HIV transmission networks across the United States.

Aldous JL, Pond SK, Poon A, Jain S, Qin H, Kahn JS, Kitahata M, Rodriguez B, Dennis AM, Boswell SL, Haubrich R, Smith DM.

Clin Infect Dis. 2012 Oct;55(8):1135-43. Epub 2012 Jul 10.


Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection.

Brumme ZL, Brumme CJ, Carlson J, Streeck H, John M, Eichbaum Q, Block BL, Baker B, Kadie C, Markowitz M, Jessen H, Kelleher AD, Rosenberg E, Kaldor J, Yuki Y, Carrington M, Allen TM, Mallal S, Altfeld M, Heckerman D, Walker BD.

J Virol. 2008 Sep;82(18):9216-27. doi: 10.1128/JVI.01041-08. Epub 2008 Jul 9.


The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.

Di Biagio A, Rusconi S, Marzocchetti A, Signori A, Schiavetti I, Bruzzone B, Monno L, Punzi G, Colao MG, Penco G, Zazzi M, De Luca A; ARCA Collaborative Group.

J Med Virol. 2014 Oct;86(10):1648-55. doi: 10.1002/jmv.24017. Epub 2014 Jul 11.


Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.

Kassaye S, Johnston E, McColgan B, Kantor R, Zijenah L, Katzenstein D.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):9-18. doi: 10.1097/QAI.0b013e31818ffdff.


Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.

Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance.

Clin Infect Dis. 2009 May 1;48(9):1296-305. doi: 10.1086/598502.


Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.

Ho SK, Perez EE, Rose SL, Coman RM, Lowe AC, Hou W, Ma C, Lawrence RM, Dunn BM, Sleasman JW, Goodenow MM.

AIDS. 2009 Aug 24;23(13):1631-40. doi: 10.1097/QAD.0b013e32832e0599.


No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.

Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Obel N, Gerstoft J.

HIV Med. 2013 Jul;14(6):362-9. doi: 10.1111/hiv.12016. Epub 2013 Feb 21.


HIV-1 subtype B/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China.

Li Y, Gu L, Han Y, Xie J, Wang H, Lv W, Song X, Li Y, Iwamoto A, Ishida T, Li T; CACT0810 group.

J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):289-97. doi: 10.1097/QAI.0000000000000473.


Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.

Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, Friedman H, Dickinson D, Frank I, Strom BL, Gaolathe T, Ndwapi N.

AIDS. 2006 Aug 1;20(12):1613-9. Erratum in: AIDS. 2006 Aug 22;20(13):1790.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk